Company
Headquarters: Riyadh, Saudi Arabia
SR6.81 Billion
SAR as of Jan. 1, 2025
US$1.81 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Al Hammadi Company For Development and Investment establishes, maintains, manages, and operates hospitals and medical centers in the Kingdom of Saudi Arabia. The company operates through Medical Services and Pharmaceuticals Products segments. It is also involved in the wholesale and retail trading of medical equipment, pharmaceutical and cosmetic products, and food and beverages; and the acquisition and rental of land for constructing buildings. In addition, the company invests in various industrial projects; and establishes, operates, and maintains commercial centers. It operates three hospitals under the Al Hammadi Hospital name in Olaya, Suwaidi, and Al Nuzha districts of Riyadh. The company was founded in 1985 and is based in Riyadh, the Kingdom of Saudi Arabia.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | SR1.13 B |
| EBITDA | SR411.2 M |
| Gross Profit TTM | SR378.8 M |
| Profit Margin | 28.75% |
| Operating Margin | 28.18% |
| Quarterly Revenue Growth | -2.40% |
Al Hammadi Company For Development and Investment has the following listings and related stock indices.
Stock: Tadawul: 4007 wb_incandescent